Table 3.
Correlation between clinicopathologic findings and HER2 status
| Clinicopathologic data | HER2 (IHC) positive | p-value | HER2 (ISH) amplification | p-value |
|---|---|---|---|---|
| Sex | NS | NS | ||
| Male | 37 (26.6) | 25 (18.0) | ||
| Female | 14 (20.3) | 8 (11.6) | ||
| Age (yr) | NS | NS | ||
| > 60 | 29 (30.5) | 18 (18.9) | ||
| ≤ 60 | 22 (19.5) | 15 (13.3) | ||
| Histologic type | < .05 | < .05 | ||
| Intestinal type | 34 (43.6) | 23 (29.5) | ||
| Diffuse type | 12 (11.0) | 6 (5.5) | ||
| Tumor differentiation | < .05 | < .05 | ||
| Grade 1, 2 | 34 (44.2) | 22 (28.6) | ||
| Grade 3, 4 | 17 (13.0) | 11 (8.4) | ||
| Depth of invasion | NS | NS | ||
| T1–2 | 13 (27.1) | 8 (16.7) | ||
| T3–4 | 38 (23.8) | 25 (15.6) | ||
| Lymph node metastasis | NS | NS | ||
| Negative | 21 (24.1) | 13 (14.9) | ||
| Positive | 30 (24.8) | 20 (16.5) | ||
| Lymphovascular invasion | NS | NS | ||
| Negative | 37 (24.5) | 23 (15.2) | ||
| Positive | 14 (24.6) | 10 (17.5) |
Values are presented as number (%).
HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; NS, not significant.